Kamada Licenses Alvotech Biosimilars In Israel
First Launch, Teriparatide, Is Slated For 2022
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
